Exosomes serve as nanoparticles to suppress tumor growth and angiogenesis in gastric cancer by delivering hepatocyte growth factor siRNA

Exosomes derived from cells have been found to mediate signal transduction between cells and to act as efficient carriers to deliver drugs and small RNA. Hepatocyte growth factor (HGF) is known to promote the growth of both cancer cells and vascular cells, and the HGF‐cMET pathway is a potential clinical target. Here, we characterized the inhibitory effect of HGF siRNA on tumor growth and angiogenesis in gastric cancer. In addition, we showed that HGF siRNA packed in exosomes can be transported into cancer cells, where it dramatically downregulates HGF expression. A cell co‐culture model was used to show that exosomes loaded with HGF siRNA suppress proliferation and migration of both cancer cells and vascular cells. Moreover, exosomes were able to transfer HGF siRNA in vivo, decreasing the growth rates of tumors and blood vessels. The results of our study demonstrate that exosomes have potential for use in targeted cancer therapy by delivering siRNA.

[1]  J. She,et al.  Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer , 2017, Oncotarget.

[2]  V. Koteliansky,et al.  Lipid nanoparticles for targeted siRNA delivery – going from bench to bedside , 2016, International journal of nanomedicine.

[3]  Yuchen Liu,et al.  Cell-derived microvesicles mediate the delivery of miR-29a/c to suppress angiogenesis in gastric carcinoma. , 2016, Cancer letters.

[4]  L. Jiao,et al.  Gene of the month: HGF , 2016, Journal of Clinical Pathology.

[5]  Xiao-long Lin,et al.  Curcumin mediates reversion of HGF-induced epithelial-mesenchymal transition via inhibition of c-Met expression in DU145 cells. , 2016, Oncology letters.

[6]  Jin Li,et al.  Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application , 2016, Gastroenterology research and practice.

[7]  X. Chen,et al.  Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse , 2015, Scientific Reports.

[8]  B. Fuchs,et al.  Signal transduction and downregulation of C-MET in HGF stimulated low and highly metastatic human osteosarcoma cells. , 2015, Biochemical and biophysical research communications.

[9]  J. Lieberman,et al.  Knocking down disease: a progress report on siRNA therapeutics , 2015, Nature Reviews Genetics.

[10]  J. Meldolesi,et al.  Ectosomes and exosomes: shedding the confusion between extracellular vesicles. , 2015, Trends in cell biology.

[11]  H. Kwan,et al.  Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion , 2015, Molecular Cancer.

[12]  Tingting Wu,et al.  HGF and c-Met in pathogenesis of endometrial carcinoma. , 2015, Frontiers in bioscience.

[13]  S. Ramakrishnan,et al.  Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models , 2014, Molecular Cancer Therapeutics.

[14]  Kyung-Hee Lee,et al.  RhoGDI2 is associated with HGF-mediated tumor invasion through VEGF in stomach cancer , 2014, Clinical & Experimental Metastasis.

[15]  Q. Ye,et al.  MicroRNA‐26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor‐cMet pathway , 2014, Hepatology.

[16]  V. Catalano,et al.  Clinical impact of the HGF/MET pathway activation in patients with advanced gastric cancer treated with palliative chemotherapy , 2014, The Pharmacogenomics Journal.

[17]  S. Akinaga,et al.  A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer , 2014, Investigational New Drugs.

[18]  Jaesung Park,et al.  Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. , 2013, ACS nano.

[19]  Y. Mohri,et al.  Clinical correlations and prognostic relevance of tissue angiogenic factors in patients with gastric cancer. , 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

[20]  Y. Taniyama,et al.  Hepatocyte growth factor stimulated angiogenesis without inflammation: differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor. , 2012, Vascular pharmacology.

[21]  M. Wood,et al.  Exosomes and the emerging field of exosome-based gene therapy. , 2012, Current gene therapy.

[22]  R. Schiffelers,et al.  Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[23]  R. Schiffelers,et al.  Exosome mimetics: a novel class of drug delivery systems , 2012, International journal of nanomedicine.

[24]  Jing Li,et al.  Secreted monocytic miR-150 enhances targeted endothelial cell migration. , 2010, Molecular cell.

[25]  J. Cryan,et al.  Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. , 2010, Molecular bioSystems.

[26]  J. Scoazec,et al.  VEGF Secretion by Neuroendocrine Tumor Cells Is Inhibited by Octreotide and by Inhibitors of the PI3K/AKT/mTOR Pathway , 2010, Neuroendocrinology.

[27]  Domenico Coppola,et al.  MicroRNA-155 Regulates Cell Survival, Growth, and Chemosensitivity by Targeting FOXO3a in Breast Cancer* , 2010, The Journal of Biological Chemistry.

[28]  S. Gambhir,et al.  Molecular Imaging of Biological Gene Delivery Vehicles for Targeted Cancer Therapy: Beyond Viral Vectors , 2010, Nuclear medicine and molecular imaging.

[29]  A. Sood,et al.  Nanomedicine based approaches for the delivery of siRNA in cancer , 2010, Journal of internal medicine.

[30]  John F. G. Atack,et al.  RNA Interference , 2010, Methods in Molecular Biology.

[31]  Katherine M Malinda,et al.  In vivo matrigel migration and angiogenesis assay. , 2009, Methods in molecular biology.

[32]  Qinxi Li,et al.  Axin determines cell fate by controlling the p53 activation threshold after DNA damage , 2009, Nature Cell Biology.

[33]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[34]  W. Stoorvogel,et al.  Exosomes contain ubiquitinated proteins. , 2005, Blood cells, molecules & diseases.

[35]  R. Johnstone.  Revisiting the road to the discovery of exosomes. , 2005, Blood cells, molecules & diseases.

[36]  Jung-Ah Cho,et al.  Exosomes: A new delivery system for tumor antigens in cancer immunotherapy , 2005, International journal of cancer.

[37]  G. Raposo,et al.  Exosomes: A Bubble Ride for Prions? , 2005, Traffic.

[38]  R. Auerbach,et al.  The sponge/Matrigel angiogenesis assay , 2004, Angiogenesis.

[39]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[40]  G. Hannon.  RNA interference : RNA , 2002 .

[41]  K. M. Malinda.  In vivo matrigel migration and angiogenesis assays. , 2001, Methods in molecular medicine.

[42]  R. Day,et al.  Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis , 1999, Oncogene.

[43]  J J Sixma,et al.  Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. , 1999, Blood.

[44]  D. Donner,et al.  Vascular Endothelial Cell Growth Factor Promotes Tyrosine Phosphorylation of Mediators of Signal Transduction That Contain SH2 Domains , 1995, The Journal of Biological Chemistry.